The influence of 18flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma

被引：15

作者：

Smith, Jason W. ^{[1
]}

Moreira, Jonathan ^{[1
]}

Abood, Gerard ^{[1
]}

Aranha, Gerard V. ^{[1
]}

Nagda, Suneel ^{[2
]}

Wagner, Robert H. ^{[3
]}

Shoup, Margo ^{[1
]}

机构：

[1] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA

[2] Loyola Univ, Med Ctr, Dept Radiat Oncol, Maywood, IL 60153 USA

[3] Loyola Univ, Med Ctr, Dept Nucl Med, Maywood, IL 60153 USA

来源：

AMERICAN JOURNAL OF SURGERY | 2009年 / 197卷 / 03期

关键词：

Esophageal carcinoma; Esophagectomy; Esophagogastric junction; FDG-JPET; Gastric carcinoma; ESOPHAGEAL CANCER; ESOPHAGOGASTRIC JUNCTION; FDG-PET; ADENOCARCINOMA; MORTALITY; TRIAL; STATISTICS; THERAPY; UTILITY; SINGLE;

D O I：

10.1016/j.amjsurg.2008.10.010

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

BACKGROUND: The influence of positron emission tomography (PET) scanning with flourodeoxyglucose (FDG) on decision making for the treatment of patients, with esophagogastric junction (EGJ) carcinoma is unclear as is the utility of the maximum standardized uptake value (SUV) as a prognostic indicator. METHODS: This study was a retrospective review of EGJ carcinoma cases at a single institution during a 5-year period. RESULTS: FDG-PET altered treatment in 13 of 64 patients (20%). Of these, 21 patients had PET scans before and after undergoing neoadjuvant chemoradiation (CRT) as well as surgery. Patients who had a decrease in SUV >50% had a 12-month disease-free survival advantage over patients a decrease in SUV <50% (93% vs 43%, P =.025). CONCLUSIONS: FDG-PET alters treatment in a significant number of patients with EGJ carcinoma. A >50% decrease in SUV after CRT is associated with an improved prognosis. (C) 2009 Published by Elsevier Inc.

引用

页码：308 / 311

页数：4

共 21 条

[1] Cancer mortality in the united states by education level and race [J].

Albano, Jessica D. ;

Ward, Elizabeth ;

Jemal, Ahmedin ;

Anderson, Robert ;

Cokkinides, Vilma E. ;

Murray, Taylor ;

Henley, Jane ;

Liff, Jonathan ;

Thun, Michael J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (18) :1384-1394

[2] Whole body 18FDG-PET and the response of esophageal cancer to induction therapy:: Results of a prospective trial [J].

Downey, RJ ;

Akhurst, T ;

Ilson, D ;

Ginsberg, R ;

Bains, MS ;

Gonen, M ;

Koong, H ;

Gollub, M ;

Minsky, BD ;

Zakowski, M ;

Turnbull, A ;

Larson, SM ;

Rusch, V .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) :428-432

[3] Medical progress - Esophageal cancer [J].

Enzinger, PC ;

Mayer, RJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (23) :2241-2252

[4] Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma [J].

Flamen, P ;

Lerut, A ;

Van Cutsem, E ;

De Wever, W ;

Peeters, M ;

Stroobants, S ;

Dupont, P ;

Bormans, G ;

Hiele, M ;

De Leyn, P ;

Van Raemdonck, D ;

Coosemans, W ;

Ectors, N ;

Haustermans, K ;

Mortelmans, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) :3202-3210

[5]

Greene F L., 2003, AJCC Cancer Staging Manual, V6th

[6] Treatment outcomes of resected esophageal cancer [J].

Hofstetter, W ;

Swisher, SG ;

Correa, AM ;

Hess, K ;

Putnam, JB ;

Ajani, JA ;

Dolormente, M ;

Francisco, R ;

Komaki, RR ;

Lara, A ;

Martin, F ;

Rice, DC ;

Sarabia, AJ ;

Smythe, WR ;

Vaporciyan, AA ;

Walsh, GL ;

Roth, JA .

ANNALS OF SURGERY, 2002, 236 (03) :376-385

[7] Cancer statistics, 2008 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Hao, Yongping ;

Xu, Jiaquan ;

Murray, Taylor ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2008, 58 (02) :71-96

[8] Cancer statistics, 2007 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Murray, Taylor ;

Xu, Jiaquan ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66

[9] Current concepts - Positron-emission tomography and assessment of cancer therapy [J].

Juweid, ME ;

Cheson, BD .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (05) :496-507

[10] PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction:: The MUNICON phase II trial [J].

Lordick, Florian ;

Ott, Katjo ;

Krause, Bern D-Joachim ;

Weber, Wolfgang A. ;

Becker, Karen ;

Stein, Hubert J. ;

Lorenzen, Sylvie ;

Schuster, Tibor ;

Wieder, Hinrich ;

Herrmann, Ken ;

Bredenkamp, Rainer ;

Hoefler, Heinz ;

Fink, Ulrich ;

Peschel, Christian ;

Schwaiger, Markus ;

Siewert, Joerg R. .

LANCET ONCOLOGY, 2007, 8 (09) :797-805

← 1 2 3 →